Lonza intends to roll out launch activities in the USA in the fourth quarter of 2011, and expand to other global regions thereafter.
Michael DeGennaro, global VP marketing and sales nutrition at Lonza, said: “Adding PS to our portfolio of branded ingredients directly represents our commitment to provide a diverse line of nutrition products and an array of formulation-friendly technical qualities. PS represents our focus of bringing solutions that meet the needs for cognitive support to our customers.”
David Rutenburg, president of Lipogen, said: “Our current primary goal is to bring high quality and efficacious brain support ingredients to the market. Lonza’s heritage and commitment to those same goals are well recognised in the nutrition industry. Collaborating our efforts with Lonza will further develop the high potential for PS and the modern PS Plus by meeting the needs of improving cognitive well being worldwide.”
PS, which may reduce the risk of dementia and cognitive dysfunction in the elderly including reducing stress and mental fatigue, joins Lonza’s portfolio of nutritional ingredients backed by scientific evidence.
PS is the only cognitive health ingredient in the US which received a qualified health claim from the FDA. Lipogen PS also obtained FDA affirmed GRAS (generally recognised as safe) status.
Source: Lonza
© FoodBev Media Ltd 2024